Vertex shares soar on cystic fibrosis drug data – Reuters


Xconomy
Vertex shares soar on cystic fibrosis drug data
Reuters
(Reuters) – Vertex Pharmaceuticals Inc's (VRTX.O) new cystic fibrosis drug Kalydeco, when combined with its experimental treatment for the disease led to significant improvement in lung function in a mid-stage study, sending Vertex shares soaring 57
Vertex Cystic Fibrosis Combo Aids Breathing in PatientsBloomberg
Vertex sizzles with upbeat Ph2 data on combo therapy for cystic fibrosisFierceBiotech
Vertex: Combined VX-809, Cystic-Fibrosis Drug Kalydeco Improved Lung FunctionWall Street Journal
Forbes -Daily Disruption -MSN Money
all 23 news articles »
This entry was posted in Health and tagged . Bookmark the permalink.

Comments are closed.